CUA 2017: Correlation of Transperineal Prostate Biopsy-Detected Cancer with Magnetic Resonance Imaging-Predicted Lesion in Patients with Previous Negative Transrectal Ultrasound-Guided Prostate Biopsies

Toronto, Ontario (UroToday.com) Introduction of multiparametric MRI (mpMRI) has drastically changed the landscape of prostate cancer (PCa) diagnostics. However, as with any diagnostic tool, learning to better select patients for appropriate use, especially in a cost-effective manner, is critically important. While originally touted to be an excellent discriminator between clinically significant prostate cancer and indolent disease, more recent results have been sobering; false negatives still persist in the range of 10-20%. In contrast, template mapping biopsies done via a transperineal approach (TPB) reported have a yield of approximately 38% in men with prior negative TRUS biopsies. 

CUA 2017: Is Tumor Location in Upper Tract Urothelial Carcinoma an Important Prognostic Factor?

Toronto, Ontario (UroToday.com) Urothelial carcinoma (UC) is often treated as one entity. However, more and more evidence is demonstrating that upper tract urothelial carcinoma (UTUC) and bladder urothelial carcinoma (BCa) may be two distinct entities. Within UTUC, there has often been debate regarding the impact of location on cancer-specific survival (CSS) – renal pelvis (RENPEL) vs ureteral (UL) UTUC may progress differently due to the environment surrounding their growth (ie depth of tissue, flow of urine, etc.). 

CUA 2017: Cystic Renal Masses: Is the Bosniak Classification System an Adequate Predictor of Survival?

Toronoto, Ontario (UroToday.com) Dr. Thenappan Chandrasekar and colleagues presented their assessment of cystic renal masses and implications of the Bosniak classification system at this morning’s GU oncology poster session at the CUA 2017 annual meeting. Previous studies have suggested that although malignancy rates may be >50%, mortality rates from these lesions are quite low.1,2 The objective of this study was to evaluate intervention rates and survival outcomes of complex renal cysts in a single-center (University Health Network, Toronto) experience. 

CUA 2017: The Prevalence and Biopsychosocial Predictors of Suicidality in Men with Prostate Cancer

Toronto, Ontario (UroToday.com) Dr. Dean Tripp and colleagues presented their study assessing prevalence and biopsychosocial predictors of suicidality in men with prostate cancer at the poster session on GU oncology at the CUA 2017 annual meeting. Prostate cancer is associated with higher depression levels than the general population, with upwards of 20% of men having clinical depression1.

CUA 2017: Population-Based Analysis of Treatment Toxicity Among Men with Castration-Resistant Prostate Cancer (mCRPC).

Toronto, Ontario (UroToday.com) At the GU oncology poster session at the 2017 CUA annual meeting, Dr. Christopher Wallis and colleagues from Toronto presented their population-based findings analyzing treatment toxicity among men with metastatic castration-resistant prostate cancer (mCRPC). Indeed, the toxicity and effectiveness of contemporary mCRPC treatments have not been assessed at a population level.

CUA 2017: Perioperative Chemotherapy does not Improve Disease-Free Survival in Upper Tract Urothelial Carcinoma: A Population-Based Analysis.

Toronto, Ontario (UroToday.com) Upper tract urothelial carcinoma (UTUC) is a rare disease, accounting for less than 5% of all urothelial cancers and with a peak incidence in the 8th and 9th decade. The role of perioperative chemotherapy remains poorly defined. Current practice in UTUC is derived from evidence related to muscle-invasive bladder cancer, where it has been shown to have a positive effect on cancer specific survival (CSS).  

CUA 2017: Changes in the Outcome of Prostate Biopsies after Preventive Task Force Recommendation Against PSA Screening.

Toronto, Ontario (UroToday.com) In 2012, the United States Preventative Services Task Force (USPSTF) updated its recommendations on prostate cancer screening, specifically recommending against PSA screening. The Canadian Task Forces on Preventive Health Care (CTFPHC) followed suit. While the criticisms of these recommendations are well-recognized (in particular, the lack of urology input in the decision making process), the recommendations stood for the past 5 years. In the past year, updated recommendations were issued again recommending PSA screening, but as a shared decision making process between patient and physician.